Detalles de la búsqueda
1.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol
; 19(2): 249-256, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29326029
2.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24657003
3.
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Breast Cancer Res
; 15(5): R86, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24060333
4.
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Breast Cancer Res Treat
; 132(3): 843-51, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21750964
5.
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.
Clin Cancer Res
; 28(10): 2167-2179, 2022 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35254385
6.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet
; 375(9712): 377-84, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20113825
7.
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification.
Genes Chromosomes Cancer
; 49(10): 901-9, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20589936
8.
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
J Cell Physiol
; 225(1): 256-65, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20506359
9.
Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence.
Cancer Sci
; 101(3): 826-30, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20132222
10.
Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
Eur J Surg Oncol
; 45(6): 969-975, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30744944
11.
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Eur J Cancer
; 105: 61-70, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30396014
12.
Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling.
Front Psychol
; 9: 1218, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30061853
13.
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
JAMA Oncol
; 4(3): 302-308, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29327055
14.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
J Clin Oncol
; 23(29): 7265-77, 2005 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-16145055
15.
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Clin Breast Cancer
; 7(4): 321-5, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17092399
16.
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Clin Cancer Res
; 11(24 Pt 1): 8715-21, 2005 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16361558
17.
Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
J Clin Oncol
; 22(9): 1614-20, 2004 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15117983
18.
[Cancer genetic counseling and quality of life: the effect of coping strategies and psychopathological symptoms during pre-test genetic counseling]. / Consulenza genetica oncologica e qualità di vita: il ruolo delle strategie di coping e della sintomatologia psicopatologica nella fase pre-testale.
Recenti Prog Med
; 106(8): 380-4, 2015 Aug.
Artículo
en Italiano
| MEDLINE | ID: mdl-26228860
19.
Corrigendum to "Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype" [Eur. J. Surg. Oncol. 45, (6) (2019) 969-975].
Eur J Surg Oncol
; 45(9): 1754, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31307816
20.
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.
Clin Cancer Res
; 20(2): 511-21, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24443618